Review Article
Role of Toll-Like Receptors and Their Downstream Molecules in the Development of Nonalcoholic Fatty Liver Disease

Kouichi Miura,1 Ekihiro Seki, 2 Hirohide Ohnishi,1 and David A. Brenner2

1 Department of Gastroenterology and Neurology, Akita University Graduate School of Medicine, 1-1-1 Hondo Akita-shi, Akita 010-8543, Japan
2 Department of Medicine, School of Medicine, University of California, San Diego, 9500 Gilman Drive, La Jolla, CA 92093, USA

Correspondence should be addressed to Kouichi Miura, miura116@doc.med.akita-u.ac.jp

Received 11 April 2010; Revised 28 October 2010; Accepted 15 December 2010

Activation of innate immunity is associated with the development of liver disease, including non-alcoholic fatty liver disease (NAFLD). In the innate immune system, Toll-like receptors (TLRs) are sensors that recognize bacterial and viral components such as lipopolysaccharide, bacterial DNA, and peptidoglycan. Recent data have demonstrated that the liver is exposed to a high load of TLR ligands due to bacterial overgrowth and increased intestinal permeability in NAFLD. Upon stimulation by these TLR ligands, hepatic immune cells produce various mediators that are involved in host defense. On the other hand, these mediators alter lipid metabolism, insulin signaling, and cell survival. Indeed, some TLR-deficient mice demonstrate lesser degrees of NAFLD even though TLR ligands are increased. This paper will highlight the recent progress on the study of TLR signaling and their downstream molecules in the development of NAFLD.

1. Introduction
Nonalcoholic steatosis is a component of metabolic syndrome, and obese people with insulin resistance frequently have fatty liver disease [1]. Although steatosis is considered a benign liver disease, a subset of steatosis includes a progressive liver disease, nonalcoholic steatohepatitis (NASH), that causes liver cirrhosis and cancer. In 1980, Ludwig et al. proposed the concept of “NASH”, steatohepatitis without a history of excess alcohol intake [2]. Currently, the term “nonalcoholic fatty liver disease (NAFLD)” is more widely used because it is difficult to diagnose NASH at an early stage without histological examinations. Thus, NAFLD comprises a spectrum of disorders ranging from simple steatosis to advanced steatohepatitis and fibrosis. Since NAFLD has become the most common liver disease and the prevalence is estimated to be 14–24% of the population in developed countries [3–5], NAFLD is a growing public health concern worldwide.

Hepatic steatosis occurs when the amount of imported and synthesized lipids exceeds the export or catabolism in hepatocytes [6–8], including (1) increased lipid delivery to the liver, (2) increased lipid uptake in hepatocytes, (3) increased de novo lipogenesis in the liver, (4) failure of lipid export, and (5) impaired hepatic mitochondrial β-oxidation of fatty acids. Steatosis is present in most patients with insulin resistance, suggesting that dysfunction of insulin signaling is closely associated with excessive accumulation of lipid in the liver. However, hepatic inflammation and consequent fibrosis are not always observed in these patients, suggesting that additional factors are required for the development of NASH.

This paper highlights Toll-like receptors (TLRs) and their downstream targets, including inflammatory cytokines and chemokines, as emerging factors in the development of NAFLD. We further review the role of nuclear factor κB (NF-κB) and c-Jun N-terminal kinase (JNK), key molecules mediating TLR signaling in NAFLD. Since hepatic resident...
macrophages, Kupffer cells, perceive various TLR ligands and produce inflammatory mediators through NF-κB and/or JNK activation [9–11], we will focus on TLR signaling in Kupffer cells.

2. The Gut-Liver Axis Is an Important Pathway in the Development of NAFLD

Gut microbiota, consisting of 15,000–35,000 species of bacteria, play a crucial role in nutrient absorption and energy storage [12–14]. Young conventionally reared mice have a 40% higher body fat and 47% higher gonadal fat content than germ-free mice, even though conventionally reared mice consume fewer calories. In addition, gnotobiotic mice exhibit a 60% increase in body fat within 2 weeks following transplantation of the gut microbiota from conventionally reared mice [15], indicating that gut microbiota contribute to nutrient acquisition. In particular, gut microbiota promote absorption of monosaccharides from the gut lumen, with resulting induction of de novo hepatic lipogenesis [15].

In addition to nutrient acquisition, gut microbiota are a source of bacterial products such as lipopolysaccharide (LPS), bacterial DNA, and peptidoglycan, which are delivered to the liver through the portal vein. In murine models of NAFLD, bacterial overgrowth is observed with compositional change as well as increased intestinal permeability by reducing the expression of tight junction proteins such as ZO-1 and occludin [16]. In human, the composition of gut microbiota differs between individuals with and without diabetes mellitus [17, 18]. Indeed, circulating bacterial components are elevated in NAFLD patients and in animal models [19–22]. As a result, liver cells are exposed to a high load of bacterial products that function as TLR ligands. Since TLR signaling is a key pathway to produce inflammatory cytokines and chemokines, the gut microbiota contribute to the development of NAFLD as a source of TLR ligands.

3. TLRs Are Associated with NAFLD

TLRs are associated with liver diseases including alcoholic liver injury, ischemia/reperfusion liver injury, liver fibrosis, and liver cancer [23, 24]. Among 13 TLRs identified in mammals, TLR2, TLR4, and TLR9 play a role in the development of NAFLD [20, 21, 25, 26]. To date, no information is available on the role of other TLRs in NAFLD. Results from gene-modified mice indicate that TLR4, and TLR9 signaling promote the progression of NAFLD.

Several groups have demonstrated that TLR4 signaling worsens NAFLD [19–21]. TLR4 is the receptor for LPS, a component of the Gram-negative bacterial cell wall. Serum LPS levels are increased in patients with hepatic steatosis caused by total parenteral nutrition or intestinal bypass [27–29]. Antibiotics treatment in these patients attenuates steatosis with decreased plasma levels of LPS [27–29]. Circulating LPS levels are elevated in most animal models of NAFLD induced by diets, including the high-fat (HF) diet, fructose-rich diet, methionine/choline-deficient (MCD) diet, and choline-deficient amino acid-defined (CDAA) diet [19–22]. Wild-type (WT) mice fed these diets show severe steatosis or steatohepatitis. In contrast, TLR4 mutant mice on these diets have less steatosis or steatohepatitis, although LPS levels are equivalent to those in WT mice. Even in mice on standard laboratory chow, continuous subcutaneous infusion of low-dose LPS results in hepatic steatosis, hepatic insulin resistance, and hepatic weight gain [30]. In addition, an intraperitoneal injection of LPS exacerbates liver injury in mice fed an MCD diet [31]. Eighty percent of intravenously injected LPSs molecules are detected in the liver within 20–30 min [32, 33]. These data indicate that the liver is the main target of LPS, and LPS-TLR4 is a key pathway for the progression of NAFLD.

TLR9 signaling contributes to the development of NASH [26]. TLR9 recognizes DNA containing an unmethylated-CpG motif that is highly expressed in bacteria-derived DNA [34]. Although bacterial DNA is detectable in blood and ascites in patients with advanced cirrhosis [35, 36], it remains unclear whether bacterial DNA is present at the early stage of liver disease and whether bacterial DNA contributes to NAFLD. We have recently demonstrated that bacterial DNA is detectable in the blood in a murine model of NASH, and that bacterial DNA binding to TLR9 contributes to the development of steatohepatitis [26]. WT mice on a CDAA diet showed severe steatohepatitis with insulin resistance. In contrast, TLR9-deficient mice had less steatohepatitis even though bacterial DNA was present in the blood [26]. In addition, TLR9-deficient mice demonstrated less insulin resistance and less fibrogenic response [26].

The role of TLR2 in NAFLD has not been well studied. TLR2 recognizes components of Gram-positive bacterial cell wall such as peptidoglycan and lipoteichoic acid [34]. At present, no studies have shown increased TLR2 ligands in NAFLD, which might be limited by current methodology. Blockade of TLR2 signaling prevents insulin resistance in HF diet-fed mice [37, 38]. In contrast, TLR2-deficient mice on an MCD diet exhibit equivalent levels of steatohepatitis but more severe steatohepatitis after LPS challenge compared to WT mice [25].

MyD88 is a key molecule in the development of metabolic syndrome including NAFLD [39, 40]. MyD88, an adaptor protein for all TLRs except for TLR3, is required for the expression of various inflammatory cytokines and chemokines [41]. MyD88-deficient mice are protected from metabolic syndrome including atherosclerosis [39, 40] and from liver injury induced by bile duct ligation or carbon tetrachloride [23, 42]. We have demonstrated that MyD88-deficient mice on a CDAA diet show less steatohepatitis with less insulin resistance compared with WT mice [26]. As expected, inflammatory cytokines and fibrogenic factors are also significantly suppressed in MyD88-deficient mice compared with WT mice fed a CDAA diet [26].

4. Endogenous TLR Ligands in NAFLD

Nonbacterial substances may function as TLR ligands; free fatty acids (FFAs) and denatured host DNA activate TLR2, TLR4 and TLR9 [43–46]. For instance, palmitate activates...
WT macrophage but not TLR4-deficient macrophages [44]. Stearic acid and palmitic acid, potential TLR4 ligands, are rich in dietary fat, and circulating FFAs are elevated in patients with NAFLD [47]. These data demonstrate an association between TLR4 and FFAs. On the other hand, some reports have demonstrated that FFAs do not bind to TLR4 [48, 49]. LPS has a high affinity for lipids such as chyomicrons and fatty acids, suggesting that contaminated LPS in the lipids may be the actual TLR4 ligand. Although the LPS-lipids complexes still have affinity to TLR4, the toxic effect of LPS is decreased [50, 51]. Thus, the concept of lipids as endogenous TLR4 ligands is still unresolved. TLR4 also recognizes oxidized phospholipid [52] and HMGB-1 [53]. To date, the role of these TLR4 ligands has not been investigated in NAFLD.

Denatured host DNA is a candidate for a TLR9 ligand in liver injury. Apoptotic hepatocyte DNA induces type I collagen and TGFβ expression in hepatic stellate cells via TLR9 [45]. Denatured host DNA also stimulates sinusoidal endothelial cells to produce interleukin (IL)-1β via TLR9 [24]. In these studies, TLR9-deficient mice were resistant to carbon tetrachloride- or acetaminophen-induced sterile liver injury. If apoptotic host DNA functions as a TLR9 ligand, NASH livers are constantly exposed to TLR9 ligands because hepatocytes undergo apoptosis and necrosis in NASH. However, the unmethylated CpG-motif is uncommon in mammalian DNAs [54], and host DNA is recognized by other DNA sensors such as DNA-dependent activator of IFN-regulatory factors and the inflammasome which sense cytosolic DNA in TLR9-independent manner [55, 56]. Although some FFAs and denatured host DNA are attractive candidates for TLR ligands, further investigations are necessary to determine whether these nonbacterial substances function as reliable TLR ligands in NAFLD.

5. Liver Cells That Perceive TLR Ligands

The liver is composed of various types of cells including hepatocytes, biliary epithelial cells, hepatic stellate cells, Kupffer cells, and sinusoidal endothelial cells. Most types of liver cells are reported to express TLRs and produce various inflammatory mediators in response to TLR ligands [10]. For instance, hepatic stellate cells and sinusoidal endothelial cells produce chemokines and inflammatory cytokines in response to a TLR4 ligand [23] and a TLR9 ligand [24], respectively. Among resident liver cells, Kupffer cells are well documented to respond to various TLR ligands such as peptidoglycan, double-stranded RNA, LPS, bacterial DNA, and probably other TLR ligands. In addition, Kupffer cells are a major source of inflammatory cytokines such as TNFα and IL-1β [9, 11]. These cytokines produced by Kupffer cells promote lipid accumulation and cell death in hepatocytes as described below in detail. These cytokines also induce hepatic stellate cells to produce profibrogenic factors such as TIMP1 and PAI-1 [26, 57, 58]. Thus, Kupffer cell-derived mediators through TLRs affect lipid metabolism, liver damage and liver fibrosis in NAFLD (Figure 1). Indeed, depletion of Kupffer cells ameliorates the progression of diet-induced steatohepatitis. Rivera et al. have reported Kupffer cell depletion delayed the development of steatohepatitis induced by an MCD diet [20]. We also have shown that depletion of Kupffer cells decreased inflammatory cytokines in mice on a CDAA diet, resulting in improvement of NASH [26]. These findings indicate that Kupffer cells play a pivotal role in the development of steatohepatitis. On the other hand, the roles of Kupffer cells in HF diet models, a simple steatosis model, are more complicated. While most of reports have shown that depletion of Kupffer cells ameliorates steatosis [59–62], one report shows an opposite effect [63]. This discrepancy may partially depend on the methodology to deplete Kupffer cells. Clodronate liposome was used to deplete Kupffer cells by intravenous injection [61] or intraperitoneal injection [62, 63]. Intravenous injection selectively depletes Kupffer cells and/or splenic macrophages but not visceral fat macrophages whereas intraperitoneal injection affects both Kupffer cells and visceral fat macrophages [23, 64]. Adipose tissue macrophages are activated in an HF diet model [63] and release various mediators such as TNFα and IL-6, which influence insulin signaling and lipid metabolism. These mediators could further activate Kupffer cells, and contribute to steatosis. Although further studies are necessary to determine the role of adipose tissue macrophages in the development of NAFLD, it is clear that Kupffer cells are important in the development of NAFLD.

6. NF-κB Activation in NAFLD

Activation of the transcriptional factor NF-κB, a downstream target for TLR-MyD88 signaling, is crucial for the inflammatory response in immune cells and is a key in the development of NAFLD [10, 11]. In NAFLD patients as well as animal models of NAFLD, NF-κB activation is observed in liver cells, including hepatocytes, hepatic stellate cells and Kupffer cells [23]. Hepatocytes respond minimally to TLR ligands in vivo, suggesting that other mediators activate NF-κB in hepatocytes [23, 65]. For instance, TNFα and IL-1β activate NF-κB in hepatocytes [26, 66]. On the other hand, TLR ligands directly activate NF-κB in Kupffer cells. TLR signaling triggers inflammatory cytokine and chemokine production in Kupffer cells through NF-κB activation [26, 67]. IKKβ activates NF-κB by the phosphorylation and subsequent degradation of Ik-β, an essential inhibitor for NF-κB. Specific deletion of IKKβ in myeloid cells including macrophages results in suppression of inflammatory cytokine production, which prevents systemic insulin resistance induced by an HF diet [68].

It is unclear whether NF-κB activation in hepatocytes leads to steatosis. Hepatocyte-specific IKKβ overexpression induces steatosis [69]. In contrast, NF-κB essential modulator (NEMO) deficiency in hepatocytes results in spontaneous steatohepatitis [70]. NEMO deficiency completely blocks NF-κB activation, indicating that NF-κB activation in hepatocytes is not a primary cause of steatosis. We and others have recently demonstrated that hepatocytes increase their lipid content in response to TNFα and IL-1β [26, 71].
In that process, TNFα and IL-1β activate NF-κB in normal hepatocytes. On the other hand, NF-κB activation by TNFα and IL-1β is blunted in lipid-laden hepatocytes [26]. NF-κB activation in hepatocytes may be required only for an initial step of lipid accumulation in the liver. Regardless of NF-κB activation in hepatocytes, inflammatory cell infiltrations and expression of F4/80, a marker for macrophage, are increased in both hepatocyte-specific IKKβ overexpressed mice and hepatocyte-specific NEMO-deficient mice [69, 70]. These data further support the concept that NF-κB activation in immune cells is a key event in the development of NAFLD.

7. JNK Activation in NAFLD

TLR-MyD88 signaling pathway activates JNK, a member of mitogen-activated protein kinases. JNK is an attractive target in the pathogenesis of NAFLD, because JNK activation plays a central role in the development of obesity and insulin resistance [72]. In patients and animals with NASH, JNK is activated in the liver, and JNK activation in immune cells results in inflammatory cytokine production [22]. Current research is analyzing the distinct roles of the JNK isoforms, JNK1 and JNK2, in the development of the metabolic syndrome including NAFLD. JNK1 promotes steatosis and inflammation in two different models of NAFLD [73]. In contrast, lack of JNK2 promotes liver injury [74]. However, it must be noted that the roles of JNKs are different in hepatocytes and Kupffer cells; JNK activation in hepatocytes is involved in cell death and insulin signaling whereas JNK activation in Kupffer cells induces inflammatory cytokine production. Recently, we and others have demonstrated the role of hematopoietic cells in the development of the metabolic syndrome including NASH [22, 75]. The results from chimeric mice generated by transplanting bone marrow cells lacking JNK1 or JNK2 into WT mice have shown that JNK1 in hematopoietic cells...
8. Inflammatory Cytokines and NAFLD

Inflammatory cytokines are important mediators in the development of NAFLD. Among inflammatory cytokines, TNFα and IL-1β have multiple functions including immune modulation, cell differentiation, proliferation, apoptosis, and energy metabolism. Indeed, expressions of TNFα and IL-1β are increased in NAFLD patients and animal models [76–79]. In contrast, most of TLR-deficient mice show decreased TNFα and IL-1β levels in NAFLD models [20, 26].

TNFα levels are increased in the liver, the adipose tissue, and the serum of NAFLD patients [76, 77]. Expression of TNF receptors is also increased in the liver of NAFLD patients [77]. Mice deficient in both TNF receptor type 1 and type 2 demonstrate less steatosis, inflammation, and liver fibrosis in a NASH diet model [80], indicating that TNF receptor signaling contributes to the development of NAFLD. So far, several mechanisms of TNFα-mediated functions are proposed: (1) insulin resistance, (2) release of fatty acids from adipose tissue, (3) regulation of lipid influx and efflux in hepatocytes, and (4) hepatocyte cell death. TNFα impairs insulin signaling by suppressing insulin receptors, insulin receptor substrate-1 and GLUT4 expressions [80], and by the expression of SOCS-3. As a result of insulin resistance, FFAs and glucose uptake are inhibited in adipocytes, whereas increased insulin levels promote FFA flux into hepatocytes and hepatic lipogenesis [81]. Moreover, TNFα increases fatty acid release from adipose tissue by promoting lipolysis, resulting in insulin resistance. In addition to impaired insulin signaling and FFA metabolism, TNFα promotes cholesterol accumulation in hepatocytes by inducing expression of LDL receptor and by inhibiting efflux of cholesterol [71]. Thus, TNFα promotes lipid accumulation in hepatocytes inducing insulin resistance, increased FFA levels, and lipid retention in the cells. Lipid-accumulated hepatocytes are vulnerable to various stimuli such as TNFα. In NASH patients, hepatocyte apoptosis and necrosis frequently occur. TNFα stimulation alone does not induce cell death in normal hepatocytes, because TNFα induces the upregulation of NF-kB-related antiapoptotic genes [66]. However, impaired lipid metabolism leads to hepatocyte apoptosis in the presence of TNFα. Hepatocytes laden with lipids have increased susceptibility to TNFα-induced cell death [82, 83]. Free cholesterol accumulation in hepatocytes depletes mitochondrial glutathione. This induces ROS generation in hepatocytes and then evokes cell death signaling [82]. In addition, lipid-accumulated hepatocytes increase the expression of ASK-1 and JNK in response to TNFα [83], which lead to cell death. These findings demonstrate that TNFα plays an important role in lipid metabolism as well as hepatocyte cell death in the development of NAFLD.

Increased IL-1β is recognized as a risk factor for the metabolic syndrome [84]. Indeed, expression of IL-1β as well as its receptor is increased in the adipose tissue of obese patients with type II diabetes [78, 79]. Single-nucleotide polymorphisms of IL-1β, which may elevate circulating IL-1β, are frequently observed in patients with metabolic syndrome including atherosclerosis [85, 86] and NASH [87]. In addition to these findings, blockade of IL-1β decreased the severity of atherosclerosis and insulin sensitivity in animal models [88, 89]. HF diet feeding, a diet model for obesity and hepatic steatosis, results in severe steatohepatitis in IL-1 receptor antagonist-deficient mice [90], suggesting that IL-1β plays an important role in NASH. The proposed functions of IL-1β are as follows: (1) lipid accumulation in hepatocytes [26, 71], (2) hepatocyte cell death [26], and (3) activation of hepatic stellate cells [26, 57, 58]. IL-1β promotes hepatic steatosis by activating PPARα [62] and diacylglycerol acyltransferase 2, an enzyme that converts diglyceride to triglyceride [26]. In addition, IL-1β promotes cell death in lipid-accumulated hepatocytes. Upon IL-1β stimulation, antiapoptotic genes are upregulated in normal hepatocytes. In contrast, proapoptotic genes such as Bax are induced in lipid-accumulated hepatocytes treated with IL-1β [26]. IL-1β induces the production of nitric oxide, generating peroxynitrite in the presence of superoxide radicals, which induces hepatocellular injury. In NAFLD, free radicals are generated by β-peroxidation of FFAs, and nitric oxide metabolites are increased in rats with NASH [91], which may further promote liver injury. Moreover, IL-1β contributes to liver fibrosis by activating hepatic stellate cells [26, 57, 58]. IL-1β induces the expression of TIMP-1 and TGFβ in hepatic stellate cells. We have shown that IL-1R-deficient mice are resistant to CDAA diet-induced liver fibrosis [26]. Thus, IL-1β is an important factor in the development of NAFLD.

9. Chemokines and NAFLD

Chemokines, strongly induced by TLR stimulation, play an important role in the development of metabolic syndrome including NAFLD. TLR4- and MyD88-deficient mice, which are resistant to metabolic syndrome, show reduced chemokine production compared with WT mice [39, 40]. MCP-1 levels are elevated in genetically obese diabetic (db/db) mice and in HF diet-fed mice. This suggests that MCP-1 and its receptor CCR2 contribute to the metabolic syndrome including obesity-related steatosis [92–95]. Indeed, MCP-1 overexpressing transgenic mice exhibit insulin resistance and hepatic steatosis as well as macrophage infiltration in adipose tissue. In contrast, MCP-1- or CCR2-deficient mice have attenuated HF diet-induced steatosis and macrophage infiltration. In these mice, inflammatory cytokine production is reduced, which could ameliorate steatohepatitis. Moreover, administration of a CCR2 antagonist improves insulin resistance. Clinical studies also demonstrate that MCP-1 levels in adipose tissue positively correlate with BMI, and patients with type II diabetes have higher serum MCP-1 levels than nondiabetes [96].
In addition to macrophage recruitment, MCP-1 promotes hepatic lipid accumulation by increasing lipid synthesis and by inhibiting lipid efflux from hepatocytes [97]. MCP-1 increases PEPCK level, resulting in de novo lipogenesis. MCP-1 decreases secretion of ApoB, which suppresses lipid efflux. Since hepatocytes do not express CCR2, hepatocytes may utilize other receptors such as CCR7 and CCR8 as the receptors for MCP-1. Thus, MCP-1 regulates lipid metabolism through macrophage recruitment and also directly on hepatocytes.

10. Perspectives

This paper summarized the role of TLRs and their downstream molecules in the development of NAFLD and showed that TLR signaling mediates steatosis, inflammation, and fibrosis. Thus, regulation of TLRs and their downstream molecules is potential targets for the therapy of NAFLD, in particular NASH. Several antagonists for TNFα, IL-1β, and CCR2 are used in NAFLD animal models [89, 93, 98–101]. In the future, these agents may be new tools for the therapy of human NAFLD. In addition to the blockade of TLR signaling, control of TLR ligands is another option for the therapy of NAFLD. Probiotics may suppress the growth of harmful intestinal bacteria and the generation of TLR ligands in the intestine. As a result, exposure to TLR ligands may be decreased in the liver. Beneficial effects of probiotics have been reported in animal NAFLD models [98, 102, 103]. Since their adverse effects are minimal in humans, randomized clinical trials of adequate size and methodology are needed for assessing the benefit of using probiotics on the NAFLD patients.

TLRs play multiple roles in multiple steps and in many hepatic cells in the development of NAFLD. In this review, we focused on the TLR signaling in Kupffer cells that produce key mediators in NAFLD. Other resident liver cells and recruited immune cells also produce many mediators that modulate the status of NAFLD in response to TLR ligands (Figure 1). Thus, better understanding of TLR signaling will provide new insight into the management and prevention of NAFLD.

Abbreviations

| Abbreviation | Description                      |
|--------------|----------------------------------|
| CCR           | C-C chemokine receptor           |
| CDAA          | Choline-deficient amino-acid defined |
| CSAA          | Choline-supplemented amino acid defined |
| FFA           | Free fatty acid                  |
| HP            | High fat                         |
| HOMA-IR       | Homeostasis model assessment of insulin resistance |
| IL            | Interleukin                       |
| IL-1R         | IL-1 receptor                     |
| JNK           | c-Jun N-terminal kinase           |
| LPS           | Lipopolysaccharide                |
| MCD           | Methionine and choline deficient  |
| MCP-1         | Monocyte chemoattractant protein-1 |
| NAFLD         | Nonalcoholic fatty liver disease  |

NASH: Nonalcoholic steatohepatitis
NEMO: NF-κB essential modulator
NF-κB: Nuclear factor κB
TNF: Tumor necrosis factor
TLR: Toll-like receptor
WT: Wild type.

Conflict of Interests

There is no conflict of interests to disclose for all authors.

Acknowledgments

The present study is supported by Takeda Science Foundation (K. Miura) and by JSPS (Grant-in-Aid for Scientific Research (C)) (K. Miura).

References

[1] F. Marra, A. Gastaldelli, G. Svegliati Baroni, G. Tell, and C. Tiribelli, “Molecular basis and mechanisms of progression of non-alcoholic steatohepatitis,” Trends in Molecular Medicine, vol. 14, no. 2, pp. 72–81, 2008.
[2] J. Ludvig, T. R. Viggiano, D. B. McGill, and B. J. Ott, “Nonalcoholic steatohepatitis. Mayo Clinic experiences with a hitherto unnamed disease,” Mayo Clinic Proceedings, vol. 55, no. 7, pp. 434–438, 1980.
[3] M. Hilden, P. Christoffersen, E. Juhl, and J. B. Dalgaard, “Liver histology in a ‘normal’ population—examinations of 503 consecutive fatal traffic casualties,” Scandinavian Journal of Gastroenterology, vol. 12, no. 5, pp. 593–597, 1977.
[4] H. Nomura, S. Kashiwagi, J. Hayashi, W. Kajiyama, S. Tani, and M. Goto, “Prevalence of fatty liver in a general population of Okinawa, Japan,” Japanese Journal of Medicine, vol. 27, no. 2, pp. 142–149, 1988.
[5] S. Bellentani, G. Saccoccio, F. Masutti et al., “Prevalence of and risk factors for hepatic steatosis in northern Italy,” Annals of Internal Medicine, vol. 132, no. 2, pp. 112–117, 2000.
[6] A. Koteish and A. M. Diehl, “Animal models of steatosis,” Seminars in Liver Disease, vol. 21, no. 1, pp. 89–104, 2001.
[7] M. W. Bradbury and P. D. Berk, “Lipid metabolism in hepatic steatosis,” Clinics in Liver Disease, vol. 8, no. 3, pp. 639–671, 2004.
[8] Q. M. Anstee and R. D. Goldin, “Mouse models in non-alcoholic fatty liver disease and steatohepatitis research,” International Journal of Experimental Pathology, vol. 87, no. 1, pp. 1–16, 2006.
[9] M. Bîlzer, F. Roggel, and A. L. Gerbes, “Role of Kupffer cells in host defense and liver disease,” Liver International, vol. 26, no. 10, pp. 1175–1186, 2006.
[10] E. Seki and D. A. Brenner, “Toll-like receptors and adaptor molecules in liver disease: update,” Hepatology, vol. 48, no. 1, pp. 322–335, 2008.
[11] G. Baffy, “Kupffer cells in non-alcoholic fatty liver disease: the emerging view,” Journal of Hepatology, vol. 51, no. 1, pp. 212–223, 2009.
[12] D. N. Frank, A. L. St. Amand, R. A. Feldman, E. C. Boedeker, N. Harpaz, and N. R. Pace, “Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases,” Proceedings of the National Academy of Sciences of the United States of America, vol. 104, no. 34, pp. 13780–13785, 2007.
Gastroenterology Research and Practice

[13] J. K. DiBaise, H. Zhang, M. D. Crowell, R. Krajmalnik-Brown, G. A. Decker, and B. E. Rittmann, “Gut microbiota and its possible relationship with obesity,” *Mayo Clinic Proceedings*, vol. 83, no. 4, pp. 460–469, 2008.

[14] C. A. Tennyson and G. Friedman, “Microecology, obesity, and probiotics,” *Current Opinion in Endocrinology, Diabetes and Obesity*, vol. 15, no. 5, pp. 422–427, 2008.

[15] F. Bäckhed, H. Ding, T. Wang et al., “The gut microbiota as an environmental factor that regulates fat storage,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 44, pp. 15718–15723, 2004.

[16] P. Brun, I. Castagliuolo, V. Di Leo et al., “Increased intestinal permeability in obese mice: new evidence in the pathogenesis of nonalcoholic steatohepatitis,” *American Journal of Physiology*, vol. 292, no. 2, pp. G518–G525, 2007.

[17] A. Santacruz, A. Marcos, J. Wärnberg et al., “Interplay between weight loss and gut microbiota composition in overweight adolescents,” *Obesity*, vol. 17, no. 10, pp. 1906–1915, 2009.

[18] N. Larsen, F. K. Vogensen, F. W. J. van den Berg et al., “Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults,” *PLoS One*, vol. 5, no. 2, Article ID e9085, 2010.

[19] D. M. L. Tsukumo, M. A. Carvalho-Filho, J. B. C. Carvalheira et al., “Loss-of-function mutation in toll-like receptor 4 prevents diet-induced obesity and insulin resistance,” *Diabetes*, vol. 56, no. 8, pp. 1986–1998, 2007.

[20] C. A. Rivera, P. Adeghoyega, N. van Rooijen, A. Tagalicud, M. Allman, and M. Wallace, “Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of nonalcoholic steatohepatitis,” *Journal of Hepatology*, vol. 47, no. 4, pp. 571–579, 2007.

[21] A. Spruss, G. Kanuri, S. Wagnerberger, S. Haub, S. C. Bischoff, and I. Bergehim, “Toll-like receptor 4 is involved in the development of fructose-induced hepatic steatosis in mice,” *Hepatology*, vol. 50, no. 4, pp. 1094–1104, 2009.

[22] Y. Kodama, T. Kisseleva, K. Iwaisako et al., “Toll-like receptor-6 in hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model,” *Journal of Hepatology*, vol. 51, no. 1, pp. 168–175, 2009.

[23] E. Seki, S. De Minicis, C. H. Österreicher et al., “TLR4 signaling and hepatic fibrosis,” *Nature Medicine*, vol. 13, no. 11, pp. 1324–1332, 2007.

[24] A. B. Imaeda, A. Watanabe, M. A. Sohail et al., “Acetaminophen-induced hepatotoxicity in mice is dependent on Tlr9 and the NALP3 inflammasome,” *Journal of Clinical Investigation*, vol. 119, no. 2, pp. 305–314, 2009.

[25] G. Szabo, A. Velayudham, L. Romic Jr., and P. Mandrekar, “Modulation of non-alcoholic steatohepatitis by pattern recognition receptors in mice: the role of toll-like receptors 2 and 4,” *Alcoholism: Clinical and Experimental Research*, vol. 29, no. 11, pp. 1405–1455, 2005.

[26] K. Miura, Y. Kodama, S. Inokuchi et al., “Toll-like receptor 9 promotes steatohepatitis via induction of interleukin-1β in mice,” *Gastroenterology*, vol. 139, no. 1, pp. 323–334.e7, 2010.

[27] I. Pappo, H. Becovier, E. M. Berry, and H. R. Freund, “Polymyxin B reduces cecal flora, TNF production and hepatic steatosis during total parenteral nutrition in the rat,” *Journal of Surgical Research*, vol. 51, no. 2, pp. 106–112, 1991.

[28] I. Pappo, H. Becovier, E. M. Berry, Y. Haviv, R. Gallily, and H. R. Freund, “Polymyxin B reduces total parenteral nutrition-associated hepatic steatosis by its antibacterial activity and by blocking deleterious effects of lipopolysaccharide,” *Journal of Parenteral and Enteral Nutrition*, vol. 16, no. 6, pp. 529–532, 1992.

[29] E. J. Drenick, J. Fisler, and D. Johnson, “Hepatic steatosis after intestinal bypass—prevention and reversal by metronidazole, irrespective of protein-calorie malnutrition,” *Gastroenterology*, vol. 82, no. 3, pp. 535–548, 1982.

[30] P. D. Cani, J. Amar, M. A. Iglesias et al., “Metabolic endotoxemia initiates obesity and insulin resistance,” *Diabetes*, vol. 56, no. 7, pp. 1761–1772, 2007.

[31] H. Kudo, T. Takahara, Y. Yata, K. Kawai, W. Zhang, and T. Sugiyama, “Lipopolysaccharide triggered TNF-α-induced hepatocyte apoptosis in a murine non-alcoholic steatohepatitis model,” *Journal of Hepatology*, vol. 51, no. 1, pp. 168–175, 2009.

[32] J. C. Mathison and R. J. Ulevitch, “The clearance, tissue distribution, and cellular localization of intravenously injected lipopolysaccharide in rabbits,” *Journal of Immunology*, vol. 123, no. 5, pp. 2133–2143, 1979.

[33] D. J. Ruitter, J. Van Der Meulen, and A. Brouwer, “Uptake by liver cell of endotoxin following its intravenous injection,” *Laboratory Investigation*, vol. 45, no. 1, pp. 38–45, 1981.

[34] T. Kawai and S. Akira, “The roles of TLRs, RLRs and NLRs in pathogen recognition,” *International Immunology*, vol. 21, no. 4, pp. 317–337, 2009.

[35] C. Guarner, J. M. González-Navajas, E. Sánchez et al., “The detection of bacterial DNA in blood of rats with CCI4-induced cirrhosis with ascites represents episodes of bacterial translocation,” *Hepatology*, vol. 44, no. 3, pp. 633–639, 2006.

[36] R. Francés, P. Zapater, J. M. González-Navajas et al., “Bacterial DNA in patients with cirrhosis and noninfected ascites mimics the soluble immune response established in patients with spontaneous bacterial peritonitis,” *Hepatology*, vol. 47, no. 3, pp. 978–985, 2008.

[37] A. M. Caricilli, P. H. Nascimento, J. R. Pauli et al., “Inhibition of toll-like receptor 2 expression improves insulin sensitivity and signaling in muscle and white adipose tissue of mice fed a high-fat diet,” *Journal of Endocrinology*, vol. 199, no. 3, pp. 399–406, 2008.

[38] R. W. Himes and C. W. Smith, “Tlr2 is critical for diet-induced metabolic syndrome in a murine model,” *FASEB Journal*, vol. 24, no. 3, pp. 731–739, 2010.

[39] H. Björkbacka, V. V. Kunjathoor, K. J. Moore et al., “Reduced atherosclerosis in MyD88-null mice links elevated serum lipopolysaccharide-inducible genes by MyD88 and Toll-like receptors,” *Nature Medicine*, vol. 10, no. 4, pp. 416–421, 2004.

[40] K. S. Michelsen, M. H. Wong, P. K. Shah et al., “Lack of toll-like receptor 4 or myeloid differentiation factor 88 reduces atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 29, pp. 10679–10684, 2004.

[41] T. Hirota, M. Yamamoto, Y. Kuma et al., “ Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-β,” *Biochemical and Biophysical Research Communications*, vol. 328, no. 2, pp. 383–392, 2005.

[42] W. E. Naugler, T. Sakurai, S. Kim et al., “Gender disparity in atherosclerosis and alters plaque phenotype in mice deficient in apolipoprotein E,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 101, no. 29, pp. 10679–10684, 2004.

[43] T. Hirota, M. Yamamoto, Y. Kuma et al., “Regulation of lipopolysaccharide-inducible genes by MyD88 and Toll/IL-1 domain containing adaptor inducing IFN-β,” *Biochemical and Biophysical Research Communications*, vol. 328, no. 2, pp. 383–392, 2005.

[44] W. E. Naugler, T. Sakurai, S. Kim et al., “Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production,” *Science*, vol. 317, no. 5834, pp. 121–124, 2007.

[45] J. H. Senn, “Toll-like receptor-2 is essential for the development of palmitate-induced insulin resistance in myotubes,” *Journal of Biological Chemistry*, vol. 281, no. 37, pp. 26865–26875, 2006.
H. Shi, M. V. Kokoeva, K. Inouye, I. Tzameli, H. Yin, and J. S. Flier, “TLR4 links innate immunity and fatty acid-induced insulin resistance,” *Journal of Clinical Investigation*, vol. 116, no. 11, pp. 3015–3025, 2006.

A. Watanabe, A. Hashmi, D. A. Gomes et al., “Apoptotic hepatocyte DNA inhibits hepatic stellate cell chemotaxis via toll-like receptor 9,” *Hepatology*, vol. 46, no. 5, pp. 1509–1518, 2007.

L. Zuo, J. He, H. Jiang, C. Xu, S. Pu, and G. Xu, “Bacterial endotoxin stimulates adipose lipolysis via toll-like receptor 4 and extracellular signal-regulated kinase pathway,” *Journal of Biological Chemistry*, vol. 284, no. 9, pp. 5913–5926, 2009.

I. T. de Almeida, H. Cortez-Pinto, G. Fidalgo, D. Rodrigues, and M. E. Camilo, “Plasma total and free fatty acids composition in human non-alcoholic steatohepatitis,” *Clinical Nutrition*, vol. 21, no. 3, pp. 219–223, 2002.

A. Schaeffl, S. Ghoshal, J. Witta, J. Zhong, W. de Villiers, and E. C. Erridge and N. J. Samani, “Saturated fatty acids do not directly stimulate toll-like receptor 4 signaling,” *Arteriosclerosis, Thrombosis, and Vascular Biology*, vol. 29, no. 11, pp. 1944–1949, 2009.

A. C. E. Vreugdenhil, C. H. Rousseau, T. Hartung, J. W. M. Greve, C. Van ‘t Veer, and W. A. Buurman, “Lipopolysaccharide (LPS)-binding protein mediates LPS detoxification by chylomicrons,” *Journal of Immunology*, vol. 170, no. 3, pp. 1399–1405, 2003.

S. Ghoshal, J. Witta, J. Zhong, W. de Villiers, and E. Eckhardt, “Chylomicrons promote intestinal absorption of lipopolysaccharides,” *Journal of Lipid Research*, vol. 50, no. 1, pp. 90–97, 2009.

Y. Imai, K. Kuba, G. G. Neely et al., “Identification of oxidative stress and Toll-like receptor 4 signaling as a key pathway of acute lung injury,” *Cell*, vol. 133, no. 2, pp. 235–249, 2008.

A. Tsung, J. R. Klune, X. Zhang et al., “HMGB1 release induced by liver ischemia involves Toll-like receptor 4-dependent reactive oxygen species production and calcium-mediated signaling,” *Journal of Experimental Medicine*, vol. 204, no. 12, pp. 2913–2923, 2007.

K. J. Stacey, G. R. Young, F. Clark et al., “The molecular basis for the lack of immunostimulatory activity of vertebrate DNA,” *Journal of Immunology*, vol. 170, no. 7, pp. 3614–3620, 2003.

A. Takaoka, Z. Wang, M. K. Choi et al., “DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response,” *Nature*, vol. 448, no. 7152, pp. 501–505, 2007.

D. A. Muruve, V. Petrelli, A. K. Zais et al., “The inflammasome recognizes cytosolic microbial and host DNA and triggers an innate immune response,” *Nature*, vol. 452, no. 7183, pp. 103–107, 2008.

H. Aoki, H. Ohnishi, K. Hama et al., “Autocrine loop between TGF-β1 and IL-1β through Smad3 and ERK-dependent pathways in rat pancreatic stellate cells,” *American Journal of Physiology*, vol. 290, no. 4, pp. C1100–C1108, 2006.

Y. P. Zhang, X. X. Yao, and X. Zhao, “Interleukin-1 beta up-regulates tissue inhibitor or matrix metalloproteinase-1 mRNA and phosphorylation of c-Jun N-terminal kinase and p38 in hepatic stellate cells,” *World Journal of Gastroenterology*, vol. 12, no. 9, pp. 1392–1396, 2006.

A. M. Neyrinck, P. D. Cani, E. M. Dewulf, F. De Bacquer, L. B. Bindels, and N. M. Delzenne, “Critical role of Kupffer cells in the management of diet-induced diabetes and obesity,” *Biochemical and Biophysical Research Communications*, vol. 385, no. 3, pp. 351–356, 2009.

W. Huang, A. Metlakunta, N. Dedouis et al., “Depletion of liver kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance,” *Diabetes*, vol. 59, no. 2, pp. 347–357, 2010.

N. Lanthier, O. Molendi-Coste, Y. Horsmans, N. Van Rooijen, P. D. Cani, and I. A. Leclercq, “Kupffer cell activation is a causal factor for hepatic insulin resistance,” *American Journal of Physiology*, vol. 298, no. 1, pp. G107–G116, 2010.

R. Stienstra, F. Saudale, C. Duval et al., “Kupffer cells promote hepatic steatosis via interleukin-1β-dependent suppression of peroxisome proliferator-activated receptor α activity,” *Hepatology*, vol. 51, no. 2, pp. 511–522, 2010.

A. H. Clementi, A. M. Gaudy, N. van Rooijen, R. H. Pierce, and R. A. Mooney, “Loss of Kupffer cells in diet-induced obesity is associated with increased hepatic steatosis, STAT3 signaling, and further decreases in insulin signaling,” *Biochimica et Biophysica Acta*, vol. 1792, no. 11, pp. 1062–1072, 2009.

N. Lanthier, Y. Horsmans, and I. A. Leclercq, “Clodronate liposomes: all sites of injection are not equal,” *Hepatology*, vol. 51, no. 2, pp. 721–722, 2010.

M. Isogawa, M. D. Robek, Y. Furuichi, and F. V. Chisari, “Toll-like receptor signaling inhibits hepatitis B virus replication in vivo,” *Journal of Virology*, vol. 79, no. 11, pp. 7269–7272, 2005.

Y. Kodama, K. Taura, K. Miura, B. Schnabl, Y. Osawa, and D. A. Brenner, “Antia apoptotic effect of c-Jun N-terminal Kinase-1 through Mcl-1 stabilization in TNF-induced hepatocyte apoptosis,” *Gastroenterology*, vol. 136, no. 4, pp. 1423–1434, 2009.

F. Marra, “Selective inhibition of NF-κB in Kupffer cells: good, but not for everything,” *Gut*, vol. 58, no. 12, pp. 1581–1582, 2009.

M. C. Arkan, A. L. Hevener, E. R. Greten et al., “IKK-β links inflammation to obesity-induced insulin resistance,” *Nature Medicine*, vol. 11, no. 2, pp. 191–198, 2005.

D. Cai, M. Yuan, D. F. Frantz et al., “Local and systemic insulin resistance resulting from hepatic activation of IKK-β and NF-κB,” *Nature Medicine*, vol. 11, no. 2, pp. 183–190, 2005.

T. Luedde, N. Beraza, V. Kotsikoris et al., “Deletion of NEMO/IKKα in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma,” *Cancer Cell*, vol. 11, no. 2, pp. 119–132, 2007.

K. L. Ma, X. Z. Ruan, S. H. Powis, Y. Chen, J. F. Moorhead, and Z. Varghese, “Inflammatory stress exacerbates lipid accumulation in hepatic cells and fatty livers of apolipoprotein E knockout mice,” *Hepatology*, vol. 48, no. 3, pp. 770–781, 2008.

J. Hirosumi, G. Tuncman, L. Chang et al., “JNK1 and JNK2 promote the development of steatohepatitis in mice,” *Hepatology*, vol. 43, no. 1, pp. 163–172, 2006.

R. Singh, Y. Wang, Y. Xiang, K. E. Tanaka, W. A. Gaarde, and M. J. Czaja, “Differential effects of JNK1 and JNK2 inhibition on murine steatohepatitis and insulin resistance,” *Hepatology*, vol. 49, no. 1, pp. 87–96, 2009.
[75] G. Solinas, C. Vilcu, J. G. Neels et al., “JNK1 in hematopoietically derived cells contributes to diet-induced inflammation and insulin resistance without affecting obesity,” Cell Metabolism, vol. 6, no. 5, pp. 386–397, 2007.

[76] G. S. Hotamisligil, N. S. Shargill, and B. M. Spiegelman, “Adipose expression of tumor necrosis factor-α: direct role in obesity-linked insulin resistance,” Science, vol. 259, no. 5091, pp. 87–91, 1993.

[77] J. M. Hui, A. Hodge, G. C. Farrell, J. G. Kench, A. Kriketos, and J. George, “Beyond insulin resistance in NASHi: TNF-α or adiponectin?” Hepatology, vol. 40, no. 1, pp. 46–54, 2004.

[78] U. Salmenniemi, E. Ruotsalainen, J. Pihlajamäki et al., “Multiple abnormalities in glucose and energy metabolism and coordinated changes in levels of adiponectin, cytokines, and adhesion molecules in subjects with metabolic syndrome,” Circulation, vol. 110, no. 25, pp. 3842–3848, 2004.

[79] C. E. Juge-Aubry, E. Somm, R. Chicheportiche et al., “Regulatory effects of interleukin (IL)-1, interferon-β, and IL-4 on the production of IL-1 receptor antagonist by human adipose tissue,” Journal of Clinical Endocrinology and Metabolism, vol. 89, no. 6, pp. 2652–2658, 2004.

[80] K. Tomita, G. Tamiya, S. Ando et al., “Tumour necrosis factor α signalling through activation of Kupffer cells plays an essential role in liver fibrosis of non-alcoholic steatohepatitis in mice,” Gut, vol. 55, no. 3, pp. 415–424, 2006.

[81] W. P. Cawthorn and J. K. Sethi, “TNF-α and adipocyte biology,” FEBS Letters, vol. 582, no. 1, pp. 117–131, 2008.

[82] M. Mari, F. Caballero, A. Colell et al., “Mitochondrial free cholesterol loading sensitizes to TNF- and Fas-mediated steatohepatitis,” Cell Metabolism, vol. 4, no. 3, pp. 185–198, 2006.

[83] W. Zhang, H. Kudo, K. Kawai et al., “Tumor necrosis factor-α accelerates apoptosis of steatotic hepatocytes from a murine model of non-alcoholic fatty liver disease,” Biochemical and Biophysical Research Communications, vol. 391, no. 4, pp. 1731–1736, 2010.

[84] J. Jager, T. Grémeaux, M. Cormont, Y. Le Marchand-Brustel, and J. F. Tanti, “Interleukin-1β-induced insulin resistance in adipocytes through down-regulation of insulin receptor substrate-1 expression,” Endocrinology, vol. 148, no. 1, pp. 241–251, 2007.

[85] K. Oda, N. Tanaka, T. Arai et al., “Polymorphisms in pro-and anti-inflammatory cytokine genes and susceptibility to atherosclerosis: a pathological study of 1503 consecutive autopsy cases,” Human Molecular Genetics, vol. 16, no. 6, pp. 592–599, 2007.

[86] J. Shen, D. K. Arnett, J. M. Peacock et al., “Interleukin1β genetic polymorphisms interact with polyunsaturated fatty acids to modulate risk of the metabolic syndrome,” Journal of Nutrition, vol. 137, no. 8, pp. 1846–1851, 2007.

[87] Y. Nozaki, T. Saibara, Y. Nemoto et al., “Polymorphisms of interleukin-1β and β3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis,” Alcoholism: Clinical and Experimental Research, vol. 28, no. 8, pp. 1065–1105, 2004.

[88] H. Kirii, T. Niwa, Y. Yamada et al., “Lack of interleukin-1β decreases the severity of atherosclerosis in apoE-deficient mice,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 23, no. 4, pp. 656–660, 2003.

[89] O. Osborn, S. E. Brownell, M. Sánchez-Alavez, D. Salomon, H. Gram, and T. Bartfai, “Treatment with an Interleukin 1 beta antibody improves glycemic control in diet-induced obesity,” Cytokine, vol. 44, no. 1, pp. 141–148, 2008.

[90] K. Isoda, S. Sawada, M. Ayaori et al., “Deficiency of interleukin-1 receptor antagonist deteriorates fatty liver and cholesterol metabolism in hypercholesterolemic mice,” Journal of Biological Chemistry, vol. 280, no. 8, pp. 7002–7009, 2005.

[91] K. Fujita, Y. Nozaki, M. Yoneda et al., “Nitric oxide plays a crucial role in the development/progression of nonalcoholic steatohepatitis in the choline-deficient, l-amino acid-defined diet-fed rat model,” Alcoholism: Clinical and Experimental Research, vol. 34, no. 1, pp. S18–S24, 2010.

[92] S. P. Weisberg, D. McCann, M. Desai, M. Rosenbaum, R. L. Leibel, and A. W. Ferrante, “Obesity is associated with macrophage accumulation in adipose tissue,” Journal of Clinical Investigation, vol. 112, no. 12, pp. 1796–1808, 2003.

[93] S. P. Weisberg, D. Hunter, R. Huber et al., “CCR2 modulates inflammatory and metabolic effects of high-fat feeding,” Journal of Clinical Investigation, vol. 116, no. 1, pp. 115–124, 2006.

[94] H. Kanda, S. Tateya, Y. Tamori et al., “MCP-1 contributes to macrophage infiltration into adipose tissue, insulin resistance, and hepatic steatosis in obesity,” Journal of Clinical Investigation, vol. 116, no. 6, pp. 1494–1505, 2006.

[95] A. E. Ostfeld, E. Sugaru, M. Thearle et al., “C-C Chemokine Receptor 2 (CCR2) regulates the hepatic recruitment of myeloid cells that promote obesity-induced hepatic steatosis,” Diabetes, vol. 59, no. 4, pp. 916–925, 2010.

[96] M. R. Chacón, J. M. Fernández-Real, C. Richart et al., “Monocyte chemoattractant protein-1 in obesity and type 2 diabetes. Insulin sensitivity study,” Obesity, vol. 15, no. 3, pp. 664–672, 2007.

[97] S. Clément, C. Juge-Aubry, A. Sgroi et al., “Monocyte chemoattractant protein-1 secreted by adipose tissue induces direct lipid accumulation in hepatocytes,” Hepatology, vol. 48, no. 3, pp. 799–807, 2008.

[98] Z. Li, S. Yang, H. Lin et al., “Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease,” Hepatology, vol. 37, no. 2, pp. 343–350, 2003.

[99] I. Pappo, H. Bercovier, E. Berry, R. Gallily, E. Feigin, and H. R. Freund, “Antitumor necrosis factor antibodies reduce hepatic steatosis during total parenteral nutrition and bowel rest in the rat,” Journal of Parenteral and Enteral Nutrition, vol. 19, no. 1, pp. 80–82, 1995.

[100] R. Barbuto, M. Milanski, M. B. Bertolo, M. J. Saad, and L. A. Velloso, “Infliximab reverses steatosis and improves insulin signal transduction in liver of rats fed a high-fat diet,” Journal of Endocrinology, vol. 194, no. 3, pp. 539–550, 2007.

[101] S. J. Yang, H. B. Iglayreger, H. C. Kadouh, and P. F. Bodary, “Inhibition of the chemokine (C-C motif) ligand 2/chemokine (C-C motif) receptor 2 pathway attenuates hyperglycaemia and inflammation in a mouse model of hepatic steatosis and lipoatrophy,” Diabetologia, vol. 52, no. 5, pp. 972–981, 2009.

[102] F. Lirussi, E. Mastropasqua, S. Orando, and R. Orlando, “Probiotics for non-alcoholic fatty liver disease and/or steatohepatitis,” Cochrane Database of Systematic Reviews, no. 1, article CD005165, 2007.

[103] A. Velayudham, A. Dolganiu, M. Ellis et al., “VSL#3 probiotic treatment attenuates fibrosis without changes in steatohepatitis in a diet-induced nonalcoholic steatohepatitis model in mice,” Hepatology, vol. 49, no. 3, pp. 989–997, 2009.